» Articles » PMID: 33484116

Severe Oligomeric Tau Toxicity Can Be Reversed Without Long-term Sequelae

Overview
Journal Brain
Specialty Neurology
Date 2021 Jan 23
PMID 33484116
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Tau is a microtubule stabilizing protein that forms abnormal aggregates in many neurodegenerative disorders, including Alzheimer's disease. We have previously shown that co-expression of fragmented and full-length tau in P301SxTAU62on tau transgenic mice results in the formation of oligomeric tau species and causes severe paralysis. This paralysis is fully reversible once expression of the tau fragment is halted, even though P301S tau expression is maintained. Whereas various strategies to target tau aggregation have been developed, little is known about the long-term consequences of reverted tau toxicity. Therefore, we studied the long-term motor fitness of recovered, formerly paralysed P301SxTAU62on-off mice. To assess the seeding competence of oligomeric toxic tau species, we also inoculated ALZ17 mice with brainstem homogenates from paralysed P301SxTAU62on mice. Counter-intuitively, after recovery from paralysis due to oligomeric tau species expression, ageing P301SxTAU62on-off mice did not develop more motor impairment or tau pathology when compared to heterozygous P301S tau transgenic littermates. Thus, toxic tau species causing extensive neuronal dysfunction can be cleared without inducing seeding effects. Moreover, these toxic tau species also lack long-term tau seeding effects upon intrahippocampal inoculation into ALZ17 mice. In conclusion, tau species can be neurotoxic in the absence of seeding-competent tau aggregates, and mice can clear these tau forms permanently without tau seeding or spreading effects. These observations suggest that early targeting of non-fibrillar tau species may represent a therapeutically effective intervention in tauopathies. On the other hand, the absent seeding competence of early toxic tau species also warrants caution when using seeding-based tests for preclinical tauopathy diagnostics.

Citing Articles

A novel monoclonal antibody generated by immunization with granular tau oligomers binds to tau aggregates at 423-430 amino acid sequence.

Soeda Y, Hayashi E, Nakatani N, Ishigaki S, Takaichi Y, Tachibana T Sci Rep. 2024; 14(1):16391.

PMID: 39060263 PMC: 11282240. DOI: 10.1038/s41598-024-65949-7.


Tau Oligomers as Pathogenic Seeds: Preparation, Characterization, and Propagation In Vitro and In Vivo.

Sengupta U, Kayed R Methods Mol Biol. 2024; 2754:147-183.

PMID: 38512666 DOI: 10.1007/978-1-0716-3629-9_9.


A novel gene therapy for methamphetamine- induced cognitive disorder with a hyper-acidified fusion variant of DnaJB1.

Zhang M, Chen C, Peng Q, Wu X, Zhou R, Ma Y Mol Ther Nucleic Acids. 2023; 31:703-716.

PMID: 36923951 PMC: 10009643. DOI: 10.1016/j.omtn.2023.02.017.


Liquid-Liquid Phase Separation Promotes Protein Aggregation and Its Implications in Ferroptosis in Parkinson's Disease Dementia.

Li M, Fan Y, Li Q, Wang X, Zhao L, Zhu M Oxid Med Cell Longev. 2022; 2022:7165387.

PMID: 36246407 PMC: 9560807. DOI: 10.1155/2022/7165387.


SARS-CoV-2 infection increases the gene expression profile for Alzheimer's disease risk.

Green R, Mayilsamy K, McGill A, Martinez T, Chandran B, Blair L Mol Ther Methods Clin Dev. 2022; 27:217-229.

PMID: 36187720 PMC: 9508696. DOI: 10.1016/j.omtm.2022.09.007.


References
1.
DeVos S, Miller R, Schoch K, Holmes B, Kebodeaux C, Wegener A . Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017; 9(374). PMC: 5792300. DOI: 10.1126/scitranslmed.aag0481. View

2.
Cascio F, Garcia S, Montalbano M, Puangmalai N, McAllen S, Pace A . Modulating disease-relevant tau oligomeric strains by small molecules. J Biol Chem. 2020; 295(44):14807-14825. PMC: 7606668. DOI: 10.1074/jbc.RA120.014630. View

3.
Hong W, Wang Z, Liu W, OMalley T, Jin M, Willem M . Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain. Acta Neuropathol. 2018; 136(1):19-40. PMC: 6647843. DOI: 10.1007/s00401-018-1846-7. View

4.
Allen B, Ingram E, Takao M, Smith M, Jakes R, Virdee K . Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002; 22(21):9340-51. PMC: 6758022. View

5.
Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A . Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res. 2006; 54(3):197-201. DOI: 10.1016/j.neures.2005.11.009. View